

Unique eye tracking as biomarker for monitoring and diagnostics in dementia therapy


01 June 2021 Maria Fellner, MBA | digitAAL Life GmbH

My grandma 35 years ago... (suffering from Alzheimer's disease)





Dementia as a rapidly growing worldwide market





New markets

Several new market opportunties due to our unique eyetracking as biomarker and multimodal activation:

DIGITAAL

- People wanting to maintain their cognitive health
- Other neurogenerative diseases, e.g. Parkinsons
- Early detection of dementia

World Alzheimer Report 2015

The Challenge: Rapid global Growth of People with Dementia

DIGITAAL

Alzheimer

Worldwide 46,8 Mio people (2015)

By 2035 100 Mio people with dementia worldwide

Cost to societies € 2 trillion

Research

No results from drug research (Pfizer, Roche stopped)

Combined behaviouroriented approach (cognition, movement, nutrition...) shows results and recommended by WHO and The Lancet Commissions

Care

Behaviour-oriented offers for mobile and stationary care under development

Efficient tools for supply sought

Currently only selective monitoring of the dementia status

Surrounding

- Family members & communities: support for care at home needed
- Slowing onset and progress of dementia for better quality of life and longer independence

Prevention

Our Solution: Daily Training – supervised or independent





digitAAL Life App explained

Our Solution: Daily Training – supervised or independent


- Multimodal training model of MAS Alzheimerhilfe (Austria)
- Developed in cooperation with
- **L** Training units with a specific theme (e.g. water)
- Sequence of exercises
 - Movement and perception exercises to warm up
 - Knowledge questions, calculations, cloze words and texts, puzzles, image pairs, trouble shooting images, audio puzzles and more

JOANNEUM N

RESEARCI

Stimulate the different senses













AT HOME Stay active - independently or with relatives

Supervised training with experts or trained volunteers

STATIONARY Use in health and care centers for individuals and in group settings Individual or group sessions, at home and in health, care and social organizations

- Many different topics, each available in 4 levels of difficulty, new content every month
- Thoroughly tested in practice, professionally wellfounded, clearly structured
- Can be used immediately without additional effort
- App raises interest and motivation to integrate multimodal training regularly into everyday life



Professionally well-founded methodology – thoroughly tested in practice

- Tested in practice in numerous field studies by
 - Austrian Red Cross
 - LKH-Univ. Klinikum Graz.
- Scientific basis from several <u>research</u> <u>projects</u>
 - under the lead of JOANNEUM RESEARCH, especially the projects <u>multimodAAL</u> and <u>PLAYTIME</u>.
 - Further development of eyetrackings with <u>MIRA from research project</u> <u>PLAYTIME</u>
- Numerous scientific publications have been published



Landeskrankenhaus - Universitätsklinikum Graz Univ.-Klinik für Neurologie A-8036 Graz, Auenbruggerplatz 22, Telefon: +43 (316) 385-81031, Fax: +43 (316) 385-14280



DIGITAAL



multimodAAL 🔊

Ρ<u>L</u>[&]Y T[®]ME</u>

Serious Challenges need serious Solutions

- Since 2011 Active & Assisted Living @ JOANNEUM RESEARCH DIGITAL
- Since 2011 mobile dementia (M.A.S.) trainings @ Sozialverein
 Deutschlandsberg
- Successful cooperation since 2015
- Digital, tablet-based solution for multimodal training as result of joint research projects
- Convincing field tests and pilot projects
- Research (JR-DIGITAL): ICT based indicators for dementia investigated for the first time worldwide
- digitAAL Life is a spin-off of JOANNEUM RESEARCH and the Sozialverein Deutschlandsberg (founded in 02/2020)



Multidisciplinary Team





Maria Fellner, MBA Co-Founder and CEO



Dr. Heinz Mayer

Co-Founder, Director of <u>institute DIGITAL</u> at JOANNEUM RESEARCH



Josef Steiner

Co-Founder, Former Chairman of Sozialverein Deutschlandsberg



Robert Hartmann

Business Development



Elke Zweytik Dementia & Care



Thomas Fruhmann

Software & IT



Raphael Marton

Medical Device Regulatory Affairs











Silvia Russegger, MSc

Head ot platform development at <u>JOANNEUM RESEARCH DIGITAL</u> 20+ years in manging positions in product management

DI Dr. Lucas Paletta Scientifice heal of research team at <u>JOANNEUM RESEARCH DIGITAL</u> & scientific lead of EU project PLAYTIME

Dr.ⁱⁿ Sandra Schüssler

1st Deputy Head of Institute of Nursing Science at MedicAL University Graz, Austria

Prof. Dr. Reinhold Schmidt

Head of <u>Department of</u> <u>Neurology, Medical</u> <u>University Graz</u>, Austria Petra Schmidt Austrian Red Cross

Dr. Stefanie Auer

Head of <u>Center for</u> <u>Dementia Studies at</u> <u>Danube University</u> <u>Krems</u>, Austria Scientific head of <u>MAS</u> <u>Alzheimerhilfe Austria</u> Dr. Liselore Snaphaan Mental Health Care Center Eindhoven, NL Prof. Dr. Inge Bongers <u>Tilburg University</u>, NL









AUS LIEBE ZUM MENSCHEN STIFTUNG










01 June 2021



USP: *only* certified medical device for therapy *and* diagnostics with a scientifc basis by clinical studies

	Therapy I	Therapy II	Diagnostics	Therapy III
Medical Device Certification	none	Therapy of dementia	Diagnostics of dementia	Personalised therapy of dementia
USP	Thematic, structured, stadium- specific training units in 4 levels	Unique certified training tool Progress monitoring, remote care cockpit and target group specific dashboards	Diagnostics <i>and</i> therapy Eyetracking as a biomarker Decision support	Therapy with diagnostics and progress monitoring -> personalised therapy
Licence types	Home Professional Lite	Home Professional Lite Professional Premium	Home Professional Lite Professional Premium Decision Support	Home Home Premium Professional Lite Professional Premium+ Decision Support+

Roadmap for Scaling-Up and Growth



until Q1/2021

First product version in German finalized (without certification as a medical product)

First licences sold

Dutch content

until 2023

Development of decision support and remote care features

Referecte study on efficacy and clinical study

Certification as a medical device for therapy and diagnostics (CE & FDA)

Markets: Europe, US

Internationalisation of product and sales

Extension of product and service portfolio


Reaching profitability

2024: 29,000 licenses installation basis

Business Model & Target Groups



B2B2C-Model:



💕 B2B:

- Inpatient facilities
- Inpatient long-term care (retirement and nursing homes)
- Day centers
- Assisted and sheltered living
- 💕 24 care
- 💕 Mobile care, ...

B2C:

- Persons with mild to moderate dementia
- Persons with mild cognitive impairment
- Elderly persons who want to remain active or make provisions for etc.



Approx. 45,000 people in 24h care in Austria.

One provider has about 400 clients

Price of an annual license: EUR 450 (incl. discount)


Turnover per year: EUR 180,000


Market share of the 24h care market: 0.88%

Target market share: 5% = EUR 1.023 million turnover in Austria alone














Use of funds:

- Development of new features
- Efficacy reference study and clinical trial
- Medical device certification for therapy and diagnostics
- Personnel for development and sales








Free test version & contact

www.DIGITAAL.life/test

- Email: <u>maria.fellner@DIGITAAL.life</u>
- Li +43 676 847 947 101
- Web: www.DIGITAAL.life



Foundation and development of digitAAL Life GmbH are supported by PreSeed and Seed financing of the BMDW and the BMK, handled by austria wirtschaftsservice (aws).



Bundesministerium Digitalisierung und Wirtschaftsstandort **Bundesministerium** Klimaschutz, Umwelt, Energie, Mobilität, Innovation und Technologie

01 June 2021